Y, the soluble/insoluble and total protein level of sumoylated and un-sumoylated proteins were also examined, bothbands of soluble and insoluble fraction of ataxin-3-68Q were denser than those of ataxin-3-68QK166R indicating the SUMOylation modification 22948146 of mutant-type ataxin-3 might enhance the stability of the protein and participate in the pathogenesis process of SCA3/MJD to a certain hPTH (1-34) cost degree. In addition, we further confirmed SUMO-1 modification decreased the degradation and enhanced the stability of mutant-type ataxin-3 by chase assay. Therefore, we have no reason to doubt that although SUMO-1 modification on K166 does not influence the UPS pathway but probably affect 
other processes such as autophagy for mutant-typeThe Effect of SUMOylation on Ataxin-Figure 3. SUMO-1 modification did not affect ataxin-3 ubiquitination. (A) order Gracillin HEK293 cells were co-transfected with GFP-ataxin-3 and FlagSUMO-1. The cells were treated with 10 mM MG132 for 12 h and subject to immunoprecipitation analysis using rabbit polyclonal antibodies against GFP. The immunoprecipitants were subject to immunoblotting analysis with the indicated antibodies. (B) HEK293 cells were transfected with GFPataxin-3 or GFP-ataxin-3K166R. The cells were treated with 10 mM MG132 for 12 h and subject to immunoprecipitation analysis using rabbit polyclonal antibodies against GFP. The immunoprecipitants were subject to immunoblotting analysis with the indicated antibodies. doi:10.1371/journal.pone.0054214.gataxin-3 degradation. Increased polyQ-expanded ataxin-3 stability might leads to multiple consequences. On the one hand, polyQexpanded ataxin-3 is more easily gathered to form aggregates. On the other hand, the 11967625 concentration of the monomer or oligomer of polyQ-expanded ataxin-3 might increases as huntingtin (26), leading to increased cytotoxicity, promotion of apoptosis, and acceleration of the pathological process in SCA3/MJD pathogenicity. PolyQ disorders are characterized pathologically by the accumulation of protein aggregates within neurons. Whether the microscopically visible inclusions play a causal role in disease pathogenesis or protect neurons from the affects of toxic proteins remains unclear [26,39]. Therefore, as a central pathological event in polyQ disorders, aggregation needs to be better understood, particularly from a therapeutic point of view. In agreement with previous studies [40], we found the amount of aggregate formation cells in mutant-type ataxin-3 as much higher than that in normal control; demonstrating polyQ expansion could induce the formation of aggregates. Although there was no significantly difference in both aggregate cell counting and density quantification between ataxin-3-68Q and ataxin-3-68QK166R, we could found the tendency that aggregate density of ataxin-3-68Q was slightly higher than that of ataxin-3-68QK166R, which support the results of insoluble fraction detection and indicate that SUMOyla-tion of mutant-type ataxin-3 might partially increase its stability and probably promote aggregate formation. It has been reported that protein aggregates could sequester polyQ proteins which affects their normal biological function [39] and finally result in polyQ diseases. SUMOylation of the polyQ proteins might influences their aggregation and toxicity. For example, SUMOylation of the polyQ-expanded AR decreases the amount of the SDS-insoluble aggregates [41], and study on huntingtin proposed that SUMOylation may explain the intriguing cell death obs.Y, the soluble/insoluble and total protein level of sumoylated and un-sumoylated proteins were also examined, bothbands of soluble and insoluble fraction of ataxin-3-68Q were denser than those of ataxin-3-68QK166R indicating the SUMOylation modification 22948146 of mutant-type ataxin-3 might enhance the stability of the protein and participate in the pathogenesis process of SCA3/MJD to a certain degree. In addition, we further confirmed SUMO-1 modification decreased the degradation and enhanced the stability of mutant-type ataxin-3 by chase assay. Therefore, we have no reason to doubt that although SUMO-1 modification on K166 does not influence the UPS pathway but probably affect other processes such as autophagy for mutant-typeThe Effect of SUMOylation on Ataxin-Figure 3. SUMO-1 modification did not affect ataxin-3 ubiquitination. (A) HEK293 cells were co-transfected with GFP-ataxin-3 and FlagSUMO-1. The cells were treated with 10 mM MG132 for 12 h and subject to immunoprecipitation analysis using rabbit polyclonal antibodies against GFP. The immunoprecipitants were subject to immunoblotting analysis with the indicated antibodies. (B) HEK293 cells were transfected with GFPataxin-3 or GFP-ataxin-3K166R. The cells were treated with 10 mM MG132 for 12 h and subject to immunoprecipitation analysis using rabbit polyclonal antibodies against GFP. The immunoprecipitants were subject to immunoblotting analysis with the indicated antibodies. doi:10.1371/journal.pone.0054214.gataxin-3 degradation. Increased polyQ-expanded ataxin-3 stability might leads to multiple consequences. On the one hand, polyQexpanded ataxin-3 is more easily gathered to form aggregates. On the other hand, the 11967625 concentration of the monomer or oligomer of polyQ-expanded ataxin-3 might increases as huntingtin (26), leading to increased cytotoxicity, promotion of apoptosis, and acceleration of the pathological process in SCA3/MJD pathogenicity. PolyQ disorders are characterized pathologically by the accumulation of protein aggregates within neurons. Whether the microscopically visible inclusions play a causal role in disease pathogenesis or protect neurons from the affects of toxic proteins remains unclear [26,39]. Therefore, as a central pathological event in polyQ disorders, aggregation needs to be better understood, particularly from a therapeutic point of view. In agreement with previous studies [40], we found the amount of aggregate formation cells in mutant-type ataxin-3 as much higher than that in normal control; demonstrating polyQ expansion could induce the formation of aggregates. Although there was no significantly difference in both aggregate cell counting and density quantification between 
ataxin-3-68Q and ataxin-3-68QK166R, we could found the tendency that aggregate density of ataxin-3-68Q was slightly higher than that of ataxin-3-68QK166R, which support the results of insoluble fraction detection and indicate that SUMOyla-tion of mutant-type ataxin-3 might partially increase its stability and probably promote aggregate formation. It has been reported that protein aggregates could sequester polyQ proteins which affects their normal biological function [39] and finally result in polyQ diseases. SUMOylation of the polyQ proteins might influences their aggregation and toxicity. For example, SUMOylation of the polyQ-expanded AR decreases the amount of the SDS-insoluble aggregates [41], and study on huntingtin proposed that SUMOylation may explain the intriguing cell death obs.
